0
BUY

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Sales and EPS outlook are good. The markets are reacting well to results from last quarter. EBITDA increased by 47% for the year. Organic growth was roughly 20% with $5M added to its cash balance. Management’s outlook is positive for 2022. Demand and growth have returned to pre-pandemic levels. Unlock Premium - Try 5i Free

0

Unlock the latest expert's opinion. Its free

Create a FREE account to see the latest opinions & get alerts about when to buy, sell or hold stocks

Unlock the latest opinion & get signals
BUY
He's owned this for a while. Likes it. They make IVF medical supplies globally to clinics and labs, an area which will continue to enjoy strong demand and growth. More and more governments and companies will cover IVF costs, another tailwind. HTL is well-positioned and grows by acquisition, and they face little competition. Not a cheap stock, but has a bright future.
0
BUY
Positive, long-term dynamics. IVF is becoming more accepted and more subsidized. Outlook is very positive. Still likes it at these prices. As a small cap, can be volatile. Might make some acquisitions to further consolidate supply, which would be a positive catalyst for the share price.
0
HOLD
A great industry to invest in the longer term. The fertility industry is booming, growing at 10% per year. It is one of the only companies you can invest in the public equity space in the industry. They are consolidating the space to present a more complete offering to clients. Management is good and makes methodical acquisitions.
0
BUY
Institutional investors keep buying this, so it's held in very well. They're a global player, selling in Europe, Asia and North America, enjoying high margins. HTL has been buying small players in a fragmented industry. They enjoy good organic growth and their recent report was positive. There may be softness in coming quarters due to the lockdown, but this is temporary. The whole sector trades at a high multiple, but he likes this company and its management.
0
HOLD
They reported very good results, but the current quarter could be soft because clinics are closed and surgeries are on hold. Their end market is impaired in parts of the US and Europe, but it's temporary. He likes its long-term prospects. Good organic growth, though the stock isn't cheap. Hang onto it, though there may be volatility due to a convertible debenture that may inject a lot of shares on the market.
0
BUY
They supply IVF products to IVF clinics. It is a well run business with good growth prospects. More and more families want to have children later in life.
0
STRONG BUY
Fertility is a booming industry, growing 10% annually in developed countries. HTL generates solid free cash flow and are making accretive tuck-in acquisitions. They acquire diligently. Eventually will be a take-out candidate by a private equity firm. They have few publicly traded peers in North America, so little competition.
0
PARTIAL BUY
They have executed very well and he recently initiated a position. They supply to fertility clinics. They have been consolidated smaller companies in the same business. He bought half a position.
0
TOP PICK
A small company that is very unique in the in vitro market. Has great long term growth fundamentals. The reproductive assistance space is set to grow globally. They don’t own the clinics, but they sell the products into clinics. One of the few public companies in the space. (Analysts’ price target is $1.52)
0
TOP PICK
They are involved in in-vitro fertilization. The industry is about $1 billion and they are the top 10 companies. As more women wait to have their first pregnancy, he thinks it will benefit by future demand. It trades at 10 times EBITDA, compared to the industry leader that trades at 30 times. It can grow through acquisition or organically or could also be a take out target. Yield 0% (Analysts’ price target is $1.55)
0
COMMENT

This is in intro fertilization, and they supply a lot of the supplies. Have been growing both organically and by acquisition. Thinks it will continue to make acquisitions.

0
Showing 1 to 12 of 12 entries
  • «
  • 1
  • »

Hamilton Thorne Ltd(HTL-X) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 1

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 1

Stockchase rating for Hamilton Thorne Ltd is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Hamilton Thorne Ltd(HTL-X) Frequently Asked Questions

What is Hamilton Thorne Ltd stock symbol?

Hamilton Thorne Ltd is a Canadian stock, trading under the symbol HTL-X on the TSX Venture Exchange (HTL-CV). It is usually referred to as TSXV:HTL or HTL-X

Is Hamilton Thorne Ltd a buy or a sell?

In the last year, 1 stock analyst published opinions about HTL-X. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Hamilton Thorne Ltd.

Is Hamilton Thorne Ltd a good investment or a top pick?

Hamilton Thorne Ltd was recommended as a Top Pick by on . Read the latest stock experts ratings for Hamilton Thorne Ltd.

Why is Hamilton Thorne Ltd stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Hamilton Thorne Ltd worth watching?

1 stock analyst on Stockchase covered Hamilton Thorne Ltd In the last year. It is a trending stock that is worth watching.

What is Hamilton Thorne Ltd stock price?

On 2022-12-05, Hamilton Thorne Ltd (HTL-X) stock closed at a price of $1.53.